The International Myeloma Foundation is the leader in globally collaborative myeloma research. The IMF is charting the course to a cure, mentoring the next generation of innovative investigators, and improving lives through better care. 

Black Swan Research Initiative® (BSRI)

Understanding that the search for a cure for multiple myeloma demands constant innovation, the IMF has launched the Black Swan Research Initiative®, a unique project to develop the first definitive cure for myeloma. Led by a multinational consortium of leading myeloma experts, we are bridging the gap from long-term remission to cure.

International Myeloma Working Group (IMWG)

IMF's International Myeloma Working Group consists of 160 leading myeloma researchers from around the world who collaborate on a broad range of myeloma research projects. With a goal to improve myeloma treatment options and diagnostic systems, their work focuses on protocols to provide a more durable remission for myeloma patients while improving quality of life, addressing the needs of both myeloma patients and the physicians who treat them.

Clinical Trials

Clinical trials offer patients access to promising new treatments which have not yet been approved. They offer an opportunity to help make new treatments available to all patients by helping to advance science. Patients in clinical trials receive high-quality care and are carefully followed.

Brian D. Novis Research Grant

The late Brian D. Novis was the co-founder of the International Myeloma Foundation (IMF). In his memory, the IMF has established annual grants to promote research into better treatments, management, prevention and a cure. These grants are made possible through donations from private individuals and are awarded annually to doctors and researchers doing work in the field of myeloma. The IMF's Brian D. Novis Research Grants are awarded in the fall, with funding beginning in January of the following year.

These awards go to doctors/researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undermined significance), as well as immunoglobulin derived amyloidosis. Second year of funding is available to recipients.